Publications by authors named "Y Y Elamin"
Article Synopsis
- - Drug resistance in EGFR-mutant non-small cell lung cancer (NSCLC) is complicated by mechanisms like pathway reactivation and fusion of receptor tyrosine kinases (RTKs), leading to challenges in treatment with tyrosine kinase inhibitors (TKIs).
- - A study involving multiple institutions analyzed 27 patients with RTK fusions identified through genetic testing, focusing on their response to dual TKI therapy, with results showing a 24% objective response rate and an 80% disease control rate overall.
- - The majority of patients had ALK or RET fusions, and those who received dual TKI treatment had a slightly lower response rate (21.4%) but no new side effects were reported, suggesting this approach
Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of neoadjuvant ICIs remains unclear. We report the influence of AGAs on treatment failure (TF) in patients with resectable NSCLC treated with neoadjuvant ICIs.
View Article and Find Full Text PDFArticle Synopsis
- Dual immune checkpoint blockade (ICB) using CTLA4 and PD-(L)1 inhibitors shows improved anti-tumor effectiveness and immune toxicity compared to PD-(L)1 inhibitors alone in advanced non-small-cell lung cancer (NSCLC) patients.
- Patients with mutations in STK11 and/or KEAP1 genes benefit more from the combination treatment compared to those receiving only PD-(L)1 inhibitors, as shown in the POSEIDON trial.
- The loss of KEAP1 serves as a strong predictor for the success of dual ICB, as it leads to a more favorable outcome by changing the tumor's immune environment to better engage CD4 and CD8 T cells for anti-tumor activity. *
Article Synopsis
- Scientists found that using two medications together, one that stops cancer and another that helps blood vessels, can help people with a certain type of lung cancer live longer without their cancer getting worse.
- They ran a study (called the RAMOSE trial) comparing one medication plus the blood vessel helper to just the medication alone.
- The results showed that people taking both medications had better outcomes, living longer without cancer progression, even though both groups experienced side effects from the treatments.
: Patients with type 2 diabetes (T2D) have a high prevalence of non-alcoholic fatty liver disease (NAFLD) (55%) and are at increased risk for developing non-alcoholic steatohepatitis, a severe form of NAFLD. Early detection of advanced fibrosis in patients with T2D and NAFLD is crucial and can prevent progression to chronic liver disease, cirrhosis, and hepatocellular carcinoma. However, screening for liver disease and risk-stratification pathways are not established in patients with T2D.
View Article and Find Full Text PDF